Efficacy and Safety of Combination Therapy With Bojungikki-tang and Pembrolizumab Monotherapy in Patients With Advanced Non-small Cell Lung Cancer

"Bojungikgitang, which is a classical formulation widely used in South Korea, China, and Japan for a long time, has been reported to have following anticancer activities.~1. Protective effect of intestine and hematopoietic organs against radiation damage~2. Improving localized radiotherapy-induced immune deterioration~3. Improving cancer-related fatigue and QOL~4. Reducing radiation or chemotherapy induced side effects"

It is a humanized antibody used in cancer immunotherapy for various types of cancer, including lung cancer. It targets the programmed cell death protein 1 (PD-1) receptor of lymphocytes. It was approved for medical use in the U.S. in 2014.